Lupinetti Allison D, Roberts Dianna B, Williams Michelle D, Kupferman Michael E, Rosenthal David I, Demonte Franco, El-Naggar Adel, Weber Randal S, Hanna Ehab Y
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4095, USA.
Cancer. 2007 Dec 15;110(12):2726-31. doi: 10.1002/cncr.23096.
Adenoid cystic carcinoma of the sinonasal tract is a rare cancer that accounts for 10% of all malignancies at this site. The objective of the current study was to evaluate prognostic factors, treatment outcomes, recurrence patterns, and survival rates for sinonasal adenoid cystic carcinoma.
A retrospective chart review was performed at an academic tertiary referral center. Between 1990 and 2004, 105 patients were evaluated for adenoid cystic carcinoma of the sinonasal tract at a single institution. Demographics, presentation, anatomic site, Tumor, Lymph Node, Metastasis (TNM) classification, pathology, treatment, recurrences, and survival were evaluated.
One hundred five patients with adenoid cystic carcinoma were evaluated, including 58 women and 47 men. Their median age was 50 years, and the mean follow-up was 47 months. The maxillary sinus (47%) and the nasal cavity (30%) were the most common primary tumor sites. The majority of patients presented with T3/T4 (76.7%), N0 (98%), M0 (97%) disease. Eighty-four percent of patients underwent surgery and received postoperative radiation as treatment for their primary disease. The local recurrence rate was 30%, and the distant metastases rate was 38%. The 5-year overall survival and disease specific survival rates were 62.9% and 70.9%, respectively.
Adenoid cystic carcinoma of the paranasal sinuses is a rare disease, and the ideal treatment paradigm has yet to be defined. The current data suggested that surgical resection with postoperative radiation therapy offers durable local control and compares favorably with historic data. Although local recurrences develop in a significant percentage of patients, survival from this disease exceeds that of other sinonasal malignancies.
鼻窦腺样囊性癌是一种罕见的癌症,占该部位所有恶性肿瘤的10%。本研究的目的是评估鼻窦腺样囊性癌的预后因素、治疗结果、复发模式和生存率。
在一家学术性三级转诊中心进行了一项回顾性病历审查。1990年至2004年间,在单一机构对105例鼻窦腺样囊性癌患者进行了评估。评估了人口统计学、临床表现、解剖部位、肿瘤、淋巴结、转移(TNM)分类、病理、治疗、复发和生存情况。
对105例腺样囊性癌患者进行了评估,其中女性58例,男性47例。他们的中位年龄为50岁,平均随访时间为47个月。上颌窦(47%)和鼻腔(30%)是最常见的原发肿瘤部位。大多数患者表现为T3/T4(76.7%)、N0(98%)、M0(97%)疾病。84%的患者接受了手术,并接受术后放疗作为原发性疾病的治疗。局部复发率为30%,远处转移率为38%。5年总生存率和疾病特异性生存率分别为62.9%和70.9%。
鼻窦腺样囊性癌是一种罕见疾病,理想的治疗模式尚未确定。目前的数据表明,手术切除加术后放疗可提供持久的局部控制,与历史数据相比具有优势。尽管相当比例的患者会出现局部复发,但该疾病的生存率超过了其他鼻窦恶性肿瘤。